Topic: medical device venture capital
The VC shop, which backed Inflazome with its second fund, will pump most of the money into European biopharma and medtech companies.
Ablative Solutions raised $77 million to bankroll clinical trials of its minimally invasive treatment for uncontrolled hypertension.
BioSig received FDA clearance for its first product, the PURE EP system, for analyzing electric heart rhythm signals.
Profusa raised more than $45 million in a series C round for its tissue-integrated biosensors.
RefleXion Medical raised more than $100 million in a series C round of funding.
The device uses optical fibers, photovoltaic cells and a rechargeable battery to address the shortcomings of existing neurostimulation products.
Zenflow will use the series A funds to trial a minimally invasive device designed to treat urinary symptoms in patients with enlarged prostates.
The telehealth startup will use the money to grow U.S. sales of its FDA-approved digital stethoscope while working to enter the Chinese market.
The startup, Flow Neuroscience, will use the money to get its first product approved in Europe.
The partners will create a joint fund that invests in technologies globally and then seeks to accelerate their progress in China.